SCHEMBL5651724

SCHEMBL5651724

CCN(CC)CCCNC(=O)c1ccc(-c2nc3cc(C(F)(F)F)cc(Cl)c3[nH]2)c(OC)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.47
METAP2 P50579 1/20 0.46
PRMT5 O14744 1/20 0.45
WDR77 Q9BQA1 1/20 0.45
ROCK2 O75116 4/20 0.43
ROCK1 Q13464 4/20 0.43
TP53 P04637 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TMEM97 Q5BJF2 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
TACR2 P21452 1/20 0.40
TACR1 P25103 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
GAA P10253 1/20 0.40
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5647616 0.93 HTT (0.43) HTTMETAP2PRMT5WDR77TP53
SCHEMBL5650796 0.90 HTT (0.45) HTTMETAP2TP53SMN1; SMN2TMEM97
SCHEMBL5653028 0.90 TP53 (0.43) HTTMETAP2PRMT5WDR77TP53
SCHEMBL5649045 0.89 FLT3 (0.46) METAP2ROCK2ROCK1MRGPRX4
SCHEMBL5651716 0.88 METAP2 (0.49) HTTMETAP2PRMT5WDR77ROCK2
SCHEMBL5654000 0.86 HTT (0.49) HTTMETAP2PRMT5WDR77ROCK2
SCHEMBL5647982 0.86 HDAC6 (0.50) HTTTP53SMN1; SMN2TMEM97SIGMAR1
SCHEMBL5653988 0.85 FLT3 (0.51) HTTMETAP2PRMT5WDR77ROCK2
SCHEMBL5650247 0.83 PRSS12 (0.50) HTTPRMT5WDR77ROCK2ROCK1
SCHEMBL5650717 0.83 FLT3 (0.45) METAP2CYP3A4CYP2C9MRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 HTT 4354/4885METAP2 3311/4885PRMT5 448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.